Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARESTOCAINE HYDROCHLORIDE vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
Local anesthesia for dental procedures requiring infiltration or nerve block anesthesia
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Articaine: approximately 1-2 hours (terminal half-life). Levonordefrin: not separately reported; vasoconstrictor effect duration supports anesthetic action. Clinical context: half-life is short, reflecting rapid metabolism by plasma esterases; clinical duration of anesthesia is prolonged by levonordefrin.
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Articaine is metabolized primarily by plasma esterases (butyrylcholinesterase) to its inactive metabolite articainic acid; levonordefrin is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Renal: primarily as metabolites (hydroxy derivatives) and unchanged drug; approximately 90% eliminated in urine as metabolites, <5% unchanged. Biliary/fecal: minor, <10%.
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
Articaine: approximately 70-80% bound, primarily to albumin. Levonordefrin: not reported.
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
Articaine: Vd ~1.0 L/kg. Clinical meaning: moderate distribution into total body water, consistent with local anesthetic profile.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
Not applicable for local anesthetic; administered parenterally (infiltration/block). By submucosal injection:100% systemically available (though redistributes locally).
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Consider 50% dose reduction. Child-Pugh C: Avoid use or reduce dose by 75%; monitor for systemic toxicity.
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
Weight-based: 0.5-1.0 mg/kg per injection site, not to exceed 3.5 mg/kg total; maximum single dose 200 mg. Adjust for age and body weight; use lower concentrations (1:100,000 epinephrine equivalent).
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
Reduce dose by 20-50% due to increased risk of cardiovascular and central nervous system effects; consider lower concentration and slower administration.
There is no FDA black box warning for Arestocaine hydrochloride.
None
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
Risk of methemoglobinemia, especially with higher doses, in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or exposure to oxidizing agents,Cardiovascular effects due to levonordefrin, including hypertension, hypotension, tachycardia, and cardiac arrhythmias; use caution in patients with cardiovascular disease, hypertension, or hyperthyroidism,Allergic reactions including anaphylaxis have been reported,Systemic toxicity due to inadvertent intravascular injection; observe proper injection technique,Use caution in patients with impaired liver function or severe renal impairment
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
Hypersensitivity to articaine, levonordefrin, or any component of the formulation,Hypersensitivity to amide-type local anesthetics or sympathomimetic amines,Severe or uncontrolled hypertension,Concurrent use of MAO inhibitors or within 14 days of discontinuation (due to risk of hypertensive crisis)
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
No significant food interactions. Avoid alcohol consumption for at least 24 hours after the procedure as it may increase the risk of bleeding at the injection site.
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause uteroplacental vasoconstriction and fetal hypoxia; avoid use during labor due to risk of maternal hypertension and fetal bradycardia.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
Minimal excretion into breast milk; M/P ratio unknown. Levonordefrin has low oral bioavailability. Considered compatible with breastfeeding; monitor infant for irritability or tachycardia. Avoid application to nipples.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
No standard dose adjustment required. Use lowest effective dose and shortest duration. Increased plasma volume in pregnancy may slightly reduce peak concentrations, but no dose adjustment is routinely recommended. Avoid use in preeclampsia or severe hypertension.
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a dental anesthetic containing articaine HCl 4% with epinephrine 1:100,000. Levonordefrin is a vasoconstrictor added to prolong local anesthesia. Avoid use in patients with sulfite sensitivity (articaine contains sodium metabisulfite). Maximum dose: 7 mg/kg (articaine) and not to exceed 0.5 mg levonordefrin per appointment. Do not inject into inflamed or infected tissues due to increased absorption. Aspirate before injection to prevent intravascular administration.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
You may experience numbness in your mouth, lips, and tongue for several hours after the injection; avoid eating or drinking hot liquids until sensation returns to prevent burns.,Do not chew on the numb area to avoid accidental injury.,If you have a history of sulfite allergy, inform your dentist before the procedure.,Contact your dentist immediately if you experience severe headache, rapid heartbeat, or difficulty breathing after the injection.,This medication can cause temporary dizziness or lightheadedness; avoid driving until the effects have worn off.
No interactions on record
"Levonordefrin, a vasoconstrictor with beta-agonist activity, may counteract the beta-blocking effects of pindolol, leading to unopposed alpha-adrenergic stimulation and potential hypertensive crisis. Additionally, pindolol's intrinsic sympathomimetic activity (ISA) may interact with levonordefrin, increasing the risk of cardiac arrhythmias and AV block due to conflicting adrenergic signaling. Clinically, this can result in severe hypertension, bradycardia, or heart block, especially in patients with underlying cardiovascular disease."
"Mianserin, a tetracyclic antidepressant with potent alpha-2-adrenergic receptor antagonism, can reduce the vasopressor response to Levonordefrin, a direct-acting alpha-1 adrenergic agonist. This interaction occurs because Mianserin blocks presynaptic alpha-2 receptors, leading to increased norepinephrine release and potential receptor desensitization, as well as possible competitive antagonism at the alpha-1 receptor. Clinically, this may result in diminished efficacy of Levonordefrin when used as a local vasoconstrictor during dental or surgical procedures, potentially leading to inadequate hemostasis or reduced local anesthesia duration."
"Levonordefrin, a sympathomimetic amine with alpha- and beta-adrenergic agonist activity, can enhance the negative dromotropic effect of arotinolol, a non-selective beta-blocker with intrinsic sympathomimetic activity. This results in additive depression of atrioventricular (AV) nodal conduction, potentially leading to prolonged PR interval, second- or third-degree AV block, and symptomatic bradycardia. Clinically, patients may present with dizziness, syncope, or hemodynamic instability, particularly in those with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARESTOCAINE HYDROCHLORIDE vs ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN, answered by our medical review team.
ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARESTOCAINE HYDROCHLORIDE and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: For local anesthesia: 1-5 m L of 2% solution (20 mg/m L) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARESTOCAINE HYDROCHLORIDE and ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies suggest risk of fetal cardiovascular abnormalities at high doses. Second/third trimesters: May cause u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.